Prolactin-secreting tumors, dopamine agonists and pregnancy: a longitudinal experience of a tertiary neuroendocrine center
Authors' conclusion
Foetal exposure to DAs during the first weeks of embryogenesis is not associated with a greater risk of complications. The transient and mild developmental disorders recorded resolved spontaneously and the prevalence was substantially overlapping with that observed in the general population.
Study context
- Population
- Women with prolactinoma who became pregnant during therapy with cabergoline (CAB) or bromocriptine (BRM); tertiary neuroendocrine centre43 women
- Participants
- 58 pregnancies
- Exposure
- Cabergoline vs bromocriptine during gestation
- CABn = 40
- BRMn = 18reference
- Outcome
- Rate of maternal-foetal complications
Methodological detailsMedical records analysed, integrated with outpatient or telephone interview
- Medical records analysed, integrated with outpatient or telephone interview
Main finding
As reported in the abstract
Maternal-foetal complications
- Child complications reported in maternal interview found exclusively in the CAB group; significant difference
- p = 0.046
Observational data: associations, not effects.
Further findings
Disease remission after the first pregnancy
- Disease remission rate
- 42.9%
- Main predictor: lower prolactin (PRL) nadir before pregnancy
- P = 0.023
- No difference between the two groups in tumor remission
- Breastfeeding did not modify the outcome
Original publication
Prolactin-secreting tumors, dopamine agonists and pregnancy: a longitudinal experience of a tertiary neuroendocrine center. Pituitary. Published 18 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →